Hype around outcomes-based contracts has been doing the rounds for some time now, but is pharma delivering the goods?
The precarious climate in the US might have spooked some pharma investors – but others are looking to targeted therapies to get more bang ...
The introduction of a new drug pricing reform in Japan has pharma up in arms. Are their fears justified?
Data generating devices may seem gimmicky, but they are poised to transform healthcare